2011 - 2020 Fourth Quarter Prevalence of Antipsychotic Use for Long-stay Residents—All Nursing Facilities												
Entity	2011 Q4	2012 Q4	2013 Q4	2014 Q4	2015 Q4	2016 Q4	2017 Q4	2018 Q4	2019 Q4	2020 Q4	% Point Difference 2011 Q4 - 2020 Q4	% Change
Kansas	26.1%	25.1%	23%¹	22.3%	N/A	19.9%	18.4%	17.0%	16.2%	16.9%¹	-9.18	-35.1%
Region 7 <sup>2</sup>	24.5%	23.4%	22.1%	20.7%	N/A	17.9%	17.3%	17.1%	16.6%	17.6%	-6.91	-28.3%
National	23.9%	22.3%	20.3%	19.1%	N/A	16.0%	15.1%	14.6%	14.0%	14.5%	-9.41	-39.4%

<sup>1</sup> Kansas ranked 45th in 2013 Quarter 4 and 39th in 2020 Quarter 4.

Entity	2011 Q4	2016 Q4	2017 Q4	2018 Q4	2019 Q4	2020 Q4	% Point Difference 2011 Q4 - 2020 Q4	% Change
Kansas	20.0%	27.2%	24.1%	17.1%	13.7%	15.6%	-4.4	-22.0%
Region 7	20.4%	27.4%	24.2%	20.9%	18.6%	19.3%	-1.08	-5.3%
National	21.4%	26.3%	23.5%	19.9%	16.8%	16.9%	-4.48	-20.9%

Source: Centers for Medicare and Medicaid Quality Measure, based on MDS 3.0 data.

https://www.cms.gov/files/document/antipsychotic-medication-use-data-report-2020q4-updated-07302021.pdf

https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/SC-Letter-16-28-Partnership-Update-Report.pdf https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/SC-Letter-14-19-Partnership-Interim-Report.pdf https://www.cms.gov/files/document/late-adopter-data-report-2020q4-updated-07302021.pdf

<sup>2</sup> Region 7 includes Iowa, Kansas, Missouri, and Nebraska.

 $^{\scriptscriptstyle 3}$  The late adopter identification is based upon 2017 Q1 Minimum Data Set data that showed:

• These nursing homes continued to have a high rate of antipsychotic medication use (2017 Q1 top quartile for the long-stay antipsychotic medication quality measure, greater than 20.29 percent);

• Their percentage of antipsychotic medication usage changed very little or increased between 2011 Q4 to 2017 Q1 (an increase or decrease of less than 6.47 percent);

• These nursing facilities were not in the top decile of schizophrenia prevalence in 2017 Q1 (18.29 percent); and

• Their rate of antipsychotic medication usage remained above the 2017 Q1 national average of 15.7 percent.

Source: https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/QSO-19-07-Enhanced-Oversight-and-Enforcement-of-Non-Improving-Late-Adopters.pdf